2012 Program Booklet - MCD Biology - University of Colorado Boulder
2012 Program Booklet - MCD Biology - University of Colorado Boulder
2012 Program Booklet - MCD Biology - University of Colorado Boulder
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Jennifer Leeds, PhD<br />
Executive Director-‐ Antibacterial Discovery<br />
Infectious Diseases Area<br />
Novartis Institute for BioMedical Research<br />
Title: Discovery and development <strong>of</strong> LFF571, a<br />
novel antibacterial for the treatment <strong>of</strong> C.<br />
difficile infection.<br />
Friday, October 12<br />
6.10-‐6.55 pm<br />
JSCBB Butcher Auditorium<br />
Abstract:<br />
Antibiotics are among the most important advances in the history <strong>of</strong> modern medicine.<br />
Antibiotics transform deadly bacterial infections into curable diseases, and enable surgical and<br />
medical innovation in nearly every therapeutic area. However, the increasing use <strong>of</strong><br />
antibiotics has contributed to the rise in drug resistant and multi-‐drug resistant pathogens<br />
both in the community and in the hospital setting. At the same time, the number <strong>of</strong> new<br />
agents to treat bacterial infections is diminishing, partly due to the difficulty in identifying ideal<br />
targets and chemical starting points as well as increasing challenges in treating patients with<br />
complex medical needs. New agents should be potent against organisms exhibiting clinically-‐<br />
relevant drug resistant phenotypes. The discovery <strong>of</strong> new chemical entities targeting<br />
unexploited mechanisms <strong>of</strong> growth inhibition is one strategy to address this hurdle. This was<br />
the origin <strong>of</strong> the drug discovery program that led us to discover LFF571. LFF571 is a new<br />
chemical entity that is currently being evaluated for safety and efficacy in patients with<br />
Clostridium difficile infection. The discovery and early development program for this novel<br />
compound will be presented.